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Caspofungin, aechinocandin, is a relatively new lipophilic antifungal drug. Little is known concerning
the pharmacokinetics of caspofungin in children. Extracorporeal membrane oxygenation (ECMO)
allows prolonged cardiopulmonary support in patients with life-threatening respiratory or cardiac
failure. Pharmacokinetics may be altered by ECMO. We describe the case of a paediatric patient on
ECMO with severe pneumonia and sepsis, who had subtherapeutic exposure of caspofungin despite
normal to high dosages of caspofungin. Therapeutic drug monitoring is warranted.
& 2012 International Society for Human and Animal Mycology. Published by Elsevier B.V
Open access under CC BY-NC-ND license.1. Introduction
Extracorporeal membrane oxygenation (ECMO) allows prolonged
cardiopulmonary support in patients with life-threatening respira-
tory or cardiac failure. Pharmacokinetics may be severely altered by
ECMO. We describe the case of a paediatric patient on ECMO with
severe pneumonia and sepsis, who had subtherapeutic exposure of
caspofungin despite normal to high dosages of caspofungin.2. Case
Two weeks after admission to a general hospital an 11 months old
baby girl was transferred to the paediatric intensive care of the
Children’s hospital, with persisting infection, neutropenia, thrombo-
penia and an imminent respiratory insufﬁciency. On admittance the
patient had a respiratory rate of 32/min, mild subcostal retractions,
crepitations on both sides and pleural rubbing. Her pulse was 170/
min, with adequate circulation and a central reﬁllo2 s.The initial
blood culture was positive for Staphyloccus aureus. Antibiotics were
started. In the next couple of days, her condition worsened and she
was intubated and mechanically ventilated. The infection parameters
did not decrease, despite multiple regimens of antibiotics. No other
pathogens were cultured. Ventilatory parameters deteriorated and
trombopenia as well as neutropenia worsened. A bronchoalveolar
lavage was performed that yielded both a positive galactomannan
test and positive cultures for Candida albicans and Candida tropicalis.and Animal Mycology. Published b
: þ31 10 7032400.
h).Veno-venous ECMOwas started (iLA-activves and the iLA membrane
ventilators, Novalung GmbH). Simultaneously, voriconazole (50 mg
twice daily) was started with a trough level of 2.3 mg/l after 4 days of
therapy (normal range 2–5mg/l). Caspofungin was started with a
loading dose of 78mg/m2, followed by 78mg/m2 once daily instead
of a standard dosage of 50 mg/m2. Because of critical illness and
expected different pharmacokinetics a higher dose was given [1].
Caspofungin blood concentrations were measured (by means of High
Pressure Liquid Chromatography with ﬂuorescence detection) at
t¼210 (7.43mg/l), 405 (3.80 mg/l), 720 (2.62 mg/l) and 1410min
(1.02mg/l) after the ﬁrst dosage. An Area under the Curve (AUC) of
caspofungin was calculated by means of WinNonLin 5.2 non-
compartmental analysis using linear-log trapezoidal method. The
AUC after the loading dose was considered subtherapeutic:
69 mg h/l (average AUC of caspofungin dosage 50mg/m2 in children
associated with a favourable outcome is 140mg h/l) [2]. Clearance
(0.04 l/h/kg) was higher than described in literature [3]. Nine days
after admittance to our children’s hospital, the clinical situation
deteriorated with severe pulmonary haemorrhage, gastrointestinal
bleeding and progressive multiorgan failure. Based on severe lung
damage and lack of improvement on maximal therapy of uncon-
trolled fungal sepsis, further treatment was deemed futile and ECMO
support was terminated. The patient died before adjusting the dose of
caspofungin.3. Discussion
This patient on ECMO had subtherapeutic exposure of caspo-
fungin despite normal to high dosages of caspofungin.y Elsevier B.V Open access under CC BY-NC-ND license.
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gin in children. A caspofungin dosage of 50 mg/m2 (70 mg/m2 on
day 1) in 10 young children 3 to 24 months of age resulted in
therapeutic caspofungin concentrations [2]. In our patient the
AUC was lower, 69 versus 140 mg h/l, 2 and clearance was higher
than described in caspofungin population kinetics [3] Trough
(1.02 mg/l) and peak concentration (7.43 mg/l) were lower com-
pared to literature (3.73 resp. 11.95 mg/l) [4]. Although dosage
was relatively high (78 mg/m2 in comparison to 50–70 mg/m2),
levels were considered subtherapeutic, indicating that ECMO, the
patient’s condition or other drug therapy can affect caspofungin
concentration. Furthermore, interpatient variability may play
a role.
The inﬂuence of ECMO on pharmacokinetics is dependent on
the characteristics of the drug and the ECMO system. Caspofungin
is freely water-soluble and has a low log P value; therefore
signiﬁcant sequestration by the ECMO circuit may not be
expected [5]. A possible explanation can be that ECMO may
inﬂuence the metabolism of caspofungin by altering the metabo-
lism of caspofungin. Metabolism could also have been inﬂuenced
by the inﬂammatory response in the patient, analogous to the
effect on CYP450 metabolism [6]. Furthermore, total volume of
the ECMO circuit was 360 ml which is about 60% of the total
circulating volume of our patient. Hemodilution may play a part
in increasing volume of distribution [7]. No information is avail-
able for caspofungin concentrations in paediatric ECMO patients.
In adults, trough and peak caspofungin concentrations were
within the normal range and the authors concluded that caspo-
fungin dosage adjustment is not warranted [3]. However, in
another case report in an adult ECMO patient, it was concluded
that ECMO highly affects caspofungin levels, resulting in low to
undetectable concentrations [8].The reasons for these differences
need to be explored, but may lay in differences between ECMO
systems, patient’s condition or interpatient variance. Moreover,
the blood concentration of caspofungin might be affected by other
drugs, but no known interacting drugs were identiﬁed in the
patient. Therapeutic drug monitoring may be a tool to dose
caspofungin in these patients.
In our patient, caspofungin was measured after the ﬁrst loading
dosage and had not reached steady state. The AUC can be increased
at steady state. However, the clearance, which will not change at
steady state, is signiﬁcantly higher in our patient than reported in
literature. This is contrary to most reports of altered PK in ECMO
patients [5]. However we found similar increases in clearance forother drugs in ECMO patients [9,10]. In conclusion, although this is a
single case report, it supports the need for therapeutic drug
monitoring in (paediatric) ECMO patients to attain concentrations
within population average that correspond with a favourable
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